Ortin Laboratories Limited Share Price NSE India S.E.

Equities

ORTINLAB

INE749B01020

Pharmaceuticals

Delayed NSE India S.E. 11:01:49 26/06/2024 BST 5-day change 1st Jan Change
20.4 INR -3.41% Intraday chart for Ortin Laboratories Limited -1.83% -11.69%

Financials

Sales 2022 82.31M 985K 77.74M Sales 2023 60.2M 721K 56.86M Capitalization 141M 1.69M 134M
Net income 2022 -3M -35.91K -2.83M Net income 2023 - 0 0 EV / Sales 2022 2.92 x
Net Debt 2022 56.52M 677K 53.39M Net Debt 2023 62.27M 745K 58.82M EV / Sales 2023 3.38 x
P/E ratio 2022
-46.1 x
P/E ratio 2023
-145 x
Employees 24
Yield 2022 *
-
Yield 2023
-
Free-Float 83%
More Fundamentals * Assessed data
Dynamic Chart
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Ortin Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Ortin Laboratories Limited Announces Board Appointments CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer CI
Ortin Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ortin Laboratories Limited Announces Executive Changes CI
Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary CI
Ortin Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Drugs Control Authority Cancels Ortin Laboratories' Manufacturing License MT
Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited CI
Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer CI
Ortin Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Ortin Laboratories Limited Announces Resignation of J R K Panduranga Rao as Independent Director CI
More news
1 day-3.41%
1 week-1.83%
Current month+18.26%
1 month+13.97%
3 months+18.60%
6 months-14.64%
Current year-11.69%
More quotes
1 week
20.15
Extreme 20.15
21.72
1 month
16.50
Extreme 16.5
21.72
Current year
16.20
Extreme 16.2
23.60
1 year
16.20
Extreme 16.2
26.35
3 years
16.20
Extreme 16.2
39.90
5 years
14.17
Extreme 14.1667
70.73
10 years
14.17
Extreme 14.1667
87.92
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 58 28/01/08
Compliance Officer - 02-08
Members of the board TitleAgeSince
Director of Finance/CFO 58 28/01/08
Chief Executive Officer - -
Director/Board Member 61 28/01/08
More insiders
Date Price Change Volume
26/06/24 20.4 -3.41% 20 560
25/06/24 21.12 -0.52% 53,588
24/06/24 21.23 +2.86% 51,425
21/06/24 20.64 +1.28% 26,298
20/06/24 20.38 -1.97% 34,523

Delayed Quote NSE India S.E., June 26, 2024 at 11:01 am

More quotes
Ortin Laboratories Limited is engaged in manufacturing and trading of pharmaceuticals, drugs, and intermediates. It manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The Company's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. It is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.
More about the company